34.25
2.24%
+0.75
After Hours:
34.25
Corbus Pharmaceuticals Holdings Inc stock is currently priced at $34.25, with a 24-hour trading volume of 96,861.
It has seen a +2.24% increased in the last 24 hours and a -5.26% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $33.54 pivot point. If it approaches the $35.05 resistance level, significant changes may occur.
Previous Close:
$33.50
Open:
$33.33
24h Volume:
96,861
Market Cap:
$359.87M
Revenue:
$1.54M
Net Income/Loss:
$-44.60M
P/E Ratio:
-3.1136
EPS:
-11
Net Cash Flow:
$-36.10M
1W Performance:
-12.72%
1M Performance:
-5.26%
6M Performance:
+567.64%
1Y Performance:
+345.38%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617 963 0100
Address
500 River Ridge Drive, Norwood, MA
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
Jul-07-20 | Initiated | ROTH Capital | Buy |
Jun-17-20 | Initiated | BTIG Research | Buy |
Mar-26-20 | Initiated | Nomura | Buy |
Apr-05-19 | Initiated | Jefferies | Buy |
Mar-20-19 | Initiated | Oppenheimer | Outperform |
Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
Dec-26-18 | Initiated | H.C. Wainwright | Buy |
Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
Oct-24-18 | Initiated | B. Riley FBR | Buy |
Jan-19-18 | Initiated | Raymond James | Outperform |
Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-08-17 | Reiterated | Noble Financial | Buy |
Sep-29-17 | Resumed | Noble Financial | Buy |
Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
GlobeNewswire Inc.
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
Zacks Investment Research
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
Zacks Investment Research
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire Inc.
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Corbus Pharmaceuticals Holdings Inc (CRBP) Revenue 2024
CRBP reported a revenue (TTM) of $1.54 million for the quarter ending September 30, 2021.
Corbus Pharmaceuticals Holdings Inc (CRBP) Net Income 2024
CRBP net income (TTM) was -$44.60 million for the quarter ending December 31, 2023, a -5.33% decrease year-over-year.
Corbus Pharmaceuticals Holdings Inc (CRBP) Cash Flow 2024
CRBP recorded a free cash flow (TTM) of -$36.10 million for the quarter ending December 31, 2023, a +3.88% increase year-over-year.
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings per Share 2024
CRBP earnings per share (TTM) was -$10.35 for the quarter ending December 31, 2023, a -1.87% decline year-over-year.
About Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Cap:
|
Volume (24h):